0.00

100.00% -2.99

Entero Therapeutics Inc (ENTO)

Overview News Price History Discussions Forecast

Entero Therapeutics Inc stock is traded at $0.00, with a volume of 0. It is down -100.00% in the last 24 hours and down -100.00% over the past month. Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Previous Close:

$2.99

Open:

24h Volume:

Relative Volume:

0.00

Market Cap:

$10.05M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-100.00%

1M Performance:

-100.00%

6M Performance:

-100.00%

1Y Performance:

-100.00%

1-Day Range:

$0.00

1-Week Range:

$0.00

52-Week Range:

$0.00

$5.84

Entero Therapeutics Inc Stock (ENTO) Company Profile

Name

Entero Therapeutics Inc

Sector

Healthcare (1134)

Industry

Biotechnology (634)

Phone

561-589-7020

Address

777 YAMATO ROAD, BOCA RATON

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

ENTO's Discussions on Twitter

Compare ENTO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTO Entero Therapeutics Inc	0.00	10.05M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	447.38	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.71	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	396.04	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	847.05	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	166.55	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Entero Therapeutics Inc Stock (ENTO) Latest News

05:03 AM

What valuation multiples suggest for Entero Therapeutics Inc. stockJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - Улправда

05:03 AM

Dec 16, 2025

ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer - Treasure Coast News

Dec 16, 2025

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy - Lubbock Avalanche-Journal

Dec 16, 2025

Dec 10, 2025

What drives Entero Therapeutics Inc stock priceVolume Profile Analysis & Low Risk Trading Alerts - earlytimes.in

Dec 10, 2025

Entero Regains Nasdaq Compliance With Grid AI Acquisition - The News Leader | Staunton, VA

Dec 10, 2025

Dec 07, 2025

GridAI Technologies announces board changes and rebranding - MSN

Dec 07, 2025

Entero Therapeutics Inc Stock Analysis and ForecastDividend Aristocrats List & Exceptional Growth Portfolio - earlytimes.in

Dec 07, 2025

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX" - Lohud

Dec 07, 2025

GridAI Technologies Corp. Announces Appointment of Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - The Florida Times-Union

Dec 07, 2025

Dec 05, 2025

GridAI Technologies Announces Board Changes and Rebranding - The Globe and Mail

Dec 05, 2025

Dec 04, 2025

GridAI Technologies Corp. Announces Board and Committee Changes - marketscreener.com

Dec 04, 2025

GridAI Technologies Corp. Appoints Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - marketscreener.com

Dec 04, 2025

GridAI Technologies (NASDAQ: GRDX) taps Marshall Chapin to lead AI data-center grid unit - Stock Titan

Dec 04, 2025

Dec 02, 2025

Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp. - MSN

Dec 02, 2025

Dec 01, 2025

GRDXGridAI Technologies Corp Stock Price and Quote - Finviz

Dec 01, 2025

Nov 29, 2025